<DOC>
	<DOCNO>NCT00026208</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give combination chemotherapy together low-dose radiation therapy work treat patient stage I stage IIA Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Low-Dose Radiation Therapy Treating Patients With Stage I Stage IIA Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate freedom progression patient stage I IIA Hodgkin 's lymphoma favorable prognosis treat Stanford V-C chemotherapy comprise cyclophosphamide , doxorubicin , vinblastine , prednisone , vincristine , bleomycin , etoposide low-dose radiotherapy . - Minimize early late effect treatment patient avoid stag laparotomy consequence , limit cumulative dos chemotherapy , reduce dose radiotherapy moderately bulky site disease . - Assess early late treatment-related toxicity , freedom second disease progression , overall survival 5 10 year patient treat regimen . OUTLINE : This multicenter study . Patients receive Stanford V-C chemotherapy comprise cyclophosphamide IV 30-60 minute weekly week 1 5 ; doxorubicin IV vinblastine IV 5 minute weekly week 1 , 3 , 5 , 7 ; oral prednisone every day week 1-8 ; vincristine IV bleomycin IV 5 minute weekly week 2 , 4 , 6 , 8 ; etoposide IV 60 minute day 1 2 week 3 7 . Beginning 2-3 week completion chemotherapy , patient undergo low-dose radiotherapy 5 day week approximately 3 week . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 80 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage I IIA Hodgkin 's lymphoma Previously untreated disease Eligible subtypes : 1 . Nodular sclerosis 2 . Mixed cellularity 3 . Classical , otherwise specify No lymphocytepredominant Hodgkin 's lymphoma No mediastinal mass onethird maximum intrathoracic diameter stand posterior chest xray No lymph node mass 10 cm great transaxial diameter No 1 extranodal site disease No constitutional ( B ) symptoms present diagnosis PATIENT CHARACTERISTICS : Age : 18 70 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Granulocyte count least 2,000/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin great 2.5 mg/dL Renal : Creatinine great 2 mg/dL Cardiovascular : Ejection fraction least 50 % patient age 50 history cardiac disease Other : HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior concurrent malignancy within past 5 year except basal cell skin cancer No medical contraindication study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : No prior endocrine therapy Radiotherapy : No prior radiotherapy Surgery : Not specify Other : No concurrent investigational drug No concurrent antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>